International Journal of Reproduction, Contraception, Obstetrics and Gynecology
Rajopadhye B et al. Int J Reprod Contracept Obstet Gynecol. 2026 Apr;15(4):1476-1486
www.ijrcog.org
pISSN 2320-1770 | eISSN 2320-1789

DOI: https://dx.doi.org/10.18203/2320-1770.ijrcog20260927

Review Article

Recent advances in oral contraceptive pills: a review of evolving formulations and innovations

Bhagyashri Rajopadhye, Aishwarya Dhakne*

Department of Pharmacology, Bharati Vidyapeeth (Deemed to Be University) Medical College, Pune, Maharashtra, India

Received: 30 December 2025
Revised: 24 February 2026
Accepted: 26 February 2026

***Correspondence:**
Dr. Aishwarya Dhakne,
E-mail: dhakneaishwarya@gmail.com

ABSTRACT

Recent innovations in oral contraceptive pills (OCPs) focus on reducing adverse effects and enhancing user control. Key advancements include low-dose/extended-cycle formulations, customization for conditions like polycystic ovary syndrome (PCOS), and improved safety profiles. User-centric features like over-the-counter (OTC) availability (Opill), smart packaging, and digital health integration further improve accessibility and adherence. Since the FDA approved Enovid in 1960, OCP development has continued to evolve. Modifications such as lower doses and extended cycles aim to minimize side effects (e.g., cardiovascular and metabolic) while maintaining efficacy. Customization addresses specific health conditions, improving patient suitability. This review aims to highlight how these developments improve efficacy, reduce side effects, and enhance convenience. This review also outlines key advancements in OCPs, associated explicitly with innovations in formulation, safety, and user-friendliness. For this purpose, this review synthesizes developments in OCP technology and delivery, based on established scientific literature and regulatory milestones. It examines formulation changes, safety enhancements, and user-focused innovations with key examples, including Opill's OTC approval and digital health tools. Thus, this review concludes that innovations in OCPs, spanning formulations, safety, and user experience, offer significant benefits that feature customization, OTC access, and digital integration, empowering women and improving adherence. These advancements also promise a more effective, accessible, and user-controlled contraceptive future.

Keywords: Accessibility enhancement**,** Innovations, OCPs, User-centered design

INTRODUCTION

The development of OCPs represents one of the most transformative advancements in reproductive medicine. The United States Food and Drug Administration's (USFDA) approval of Enovid in 1960 marked the first reliable, female-controlled contraceptive method.[1] Early high-dose formulations contained high doses of estrogen and progestins, which although effective, were associated with significant adverse effects including thromboembolic events, metabolic disturbances and cardiovascular risks. These safety concerns became the primary driving force for continuous innovation over the following six decades toward safer, more tailored, and accessible options.[2-4]

Modern OCPs incorporate several key advancements that reflect pharmacologic and regimen-based approaches. Low-dose estrogen and progestin formulations reduce common side effects such as weight gain, mood changes, and breast tenderness; while decreasing cardiovascular and metabolic riskes.[5]

These advances have improved long term tolerability and acceptability, particularly among women requiring extended contraceptive use.

Regimen based innovation have further enhanced the clinical utility of OCPs. Extended-cycle and continuous regimens limit menstrual frequency, reduce dysmenorrhea, anaemia, and menstrual-related productivity loss while also improving adherence.[6] Additionally, formulations have been adapted for condition-specific needs-such as anti-androgenic options for PCOS and extended-cycle regimens for endometriosis-to enhance both therapeutic and contraceptive benefits.[4,7]

Technological advancements and delivery innovations have further contributed to a more user-centred contraceptive experience. Smart blister packs, app-based reminders, and digital adherence tracking tools address missed doses and improve long-term continuation.[8-10]

Non-oral hormonal delivery systems, including transdermal patches and vaginal rings, provide steady hormone release without daily dose administration, offering additional flexibility and expanding the range of user-centred contraceptive choice.[11]

A major milestone in accessibility was achieved in July 2023 with the FDA approval of OTC norgestrel (Opill), which removed the prescription requirement and has potentially reduced disparities in contraceptive access.[12,13] This regulatory change reflects growing public interest in OTC contraceptive availability and addresses barriers for populations with limited healthcare access.[14]

Taking into consideration the above-stated facts, the evolution of OCPs illustrates an ongoing shift toward personalized, safe, and user-centric contraceptive care. Thus, with the continued progress and focusing on integrating pharmacologic innovation, tailored regimens, and enhanced delivery systems will help to optimize and expand condition-specific formulations to better meet the diverse reproductive needs of women worldwide.[1,3,6,13]



Figure 1: Classification of estrogens and progestins used in oral contraceptives based on generation, source, and blood pressure effects.[2]

Synthetic and natural estrogens and progestins used in oral contraceptive formulations can be categorized by their generation and origin, with implications for safety and tolerability, as seen in the above Figure 1. The figure highlights greater effects of synthetic estrogens like ethinyl estradiol on blood pressure (BP) as compared to natural estrogens.[2] It also highlights the 3rd generation progestins, including dienogest and drospirenone, which demonstrate improved safety profiles and targeted therapeutic benefits. Further, progestins are grouped by chemical structure and generational development, which reflects ongoing refinement to balance contraceptive efficacy.

HISTORICAL CONTEXT AND INNOVATION IMPERATIVE

The 1960 was a landmark in the history of OCP introduction, as the FDA approved Enovid, the first OCP, representing a pivotal milestone in reproductive medicine.[1] This achievement, pioneered through the advocacy of Margaret Sanger and the financial support of

Katharine McCormick, marked a defining moment in reproductive health by introducing women with control over their fertility.[1] Furthermore, this breakthrough reshaped reproductive autonomy, enabling women to plan pregnancies with unprecedented reliability. The earliest formulations contained mestranol and first-generation progestins in relatively high doses. Although highly effective in suppressing ovulation, these preparations produced frequent adverse effects including thromboembolism and cardiovascular complications which became apparent during widespread population use in 1960s and 1970s.[2]

Recognition of estrogen-related complications initiated the first major wave of pharmaceutical innovation. Subsequently generation of OCPs progressively reduced estrogen content from more than 150 µg to modern preparations containing 20-30 µg of ethinly estradiol. This reduction significantly improved safety by lowering hepatic induction of clotting factors, angiotensinogen production and triglyceride synthesis. The second phase of development focused on progestin modification. Early progestins possessed androgenic activity, contributing to acne, adverse lipid changes and weight gain. Later agents such as desogestrel, norgestimate and drospirenone were developed to provide strong ovulation suppression while minimizing androgenic and mineralocorticoid effects. The most recent phase of innovation involves altering the estrogen component itself. Estetrol, a naturally occurring fetal estorgen, has been introduced as an alternative to ethinly estradiol. Unlike ethinly estradiol, estetrol exerts weaker hepatic stimulation and may therefore reduce thrombotic risk while preserving contraceptive efficacy.[3] This shift reflects a fundamental change in design philosophy, rather than minimizing estrogen dose alone, modern research attempts to modify pharmacodynamics.

Since then, continuous innovation and refinement to balance contraceptive efficacy have led to the need for safer, more adaptable, and user-friendly contraceptive options that can improve user convenience and diverse clinical and lifestyle context.[3,4] Beyond preventing unintended pregnancies, contemporary contraceptive development emphasizes enhancing informed decision-making, minimizing health risks, and accommodating diverse medical and lifestyle needs.[5,6]

FORMULATION ADVANCEMENTS

Pharmaceutical innovations in OCPs have primarily aimed to preserve ovulation suppression while reducing systemic hormonal exposure. Early combined pills relied on high estrogen concentrations to ensure contraceptive reliability; however, it later became evident that the majority of serious adverse events were dose-related rather than mechanism-related.

Consequently, contemporary formulations attempt to achieve endocrine control with minimal physiologic disturbance.

Traditional 21/7 regimens were originally designed to mimic the natural menstrual cycle rather than for medical necessity. Withdrawal bleeding occurs because of hormone-free intervals, not because of physiologic need. Extended and continuous regimens, such as the 84/7 schedule, offer fewer menstrual cycles per year, improving adherence and alleviating dysmenorrhea, anaemia, and menstrual-related productivity loss.[8,9] Advances in pharmacology also enable personalized OCP selection-including anti-androgenic formulations for PCOS and extended-cycle pills for endometriosis, thereby optimizing both contraceptive and therapeutic outcomes.[4,10]

Additionally, alternative delivery systems such as transdermal patches (e.g., Xulane) and vaginal rings (e.g., NuvaRing) expand contraceptive options by providing steady hormone release without daily dosing, enhancing convenience and adherence.[11,12]

CLINICAL IMPLICATIONS

Modern OCP designs contribute to improved clinical outcomes through risk reduction and enhanced usability. Lower-dose and targeted hormonal formulations decrease metabolic and cardiovascular risks-including insulin resistance, dyslipidemia, and venous thromboembolism (VTE)-while reducing the likelihood of drug-drug interactions.[13] Estrogen stimulates hepatic production of coagulation factors II, VII, IX and X while reducing antithrombin III activity. Lower estrogen doses have substantially reduced, but not eliminated, this risk. Importantly, absolute risk remains low in healthy non-smoking women, and pregnancy itself carries a higher thrombotic risk than modern OCP use.

Enzyme-inducing medications (e. g., rifampicin, certain antileptics) accelerate estrogen metabolism and may reduce contraceptive effectiveness. In such patients, higher dose or non-oral methods are preferred. Conversely progestin only pills provide safer alternatives for women with contraindications to estrogen, including smokers above 35 years, migraine with aura and history of thromboembolism.[13]

Flexible dosing schedules, multiple hormonal combinations, and non-oral delivery routes promote a patient-centered approach, allowing alignment with individual health needs, comorbidities, and lifestyle preferences.[15] Collectively, these innovations enable broader adoption, improve adherence, and reproductive autonomy for women worldwide.[3,14]

OCPs are now widely prescribed for several gynaecological and endocrine conditions: PCOS-suppression of ovarian and androgen production. Acne and hirsutism-suppression of androgens, endometriosis-endometrial atrophy and reduced ectopic endometrial activity, menorrhagia-endometrial stabilization and reduced bleeding and menstrual migraine-elimination of hormonal fluctuation.

These benefits arise from hypothalamic-pituitary-ovarian axis suppression rather than contraception itself, demonstrating how OCPs have transitioned into a therapeutic hormonal regulator. The increasing incidence of PCOS, closely associated with contemporary patterns of physical inactivity, energy-dense nutrition, psychosocial stress, and circadian disruption, has substantially influenced prescribing trends in reproductive pharmacotherapy. OCPs are now widely utilized not solely for pregnancy prevention but as first-line agents for the endocrine modulation of PCOS. Through suppression of luteinizing hormone secretion and enhancement of hepatic sex hormone-binding globulin synthesis, combined hormonal formulations reduce circulating free androgens and promote menstrual regularity. This therapeutic application reflects a broader shift in the clinical positioning of oral contraceptives-from exclusive contraceptive agents to multifunctional endocrine regulators addressing the metabolic-reproductive interface. Consequently, the rising burden of lifestyle-associated hormonal dysregulation has reinforced the central role of oral contraceptives in contemporary management strategies for PCOS and related hyperandrogenic states.

RECENT ADVANCES

Recent developments in OCPs reflect a shift from purely pharmacologic improvement toward integration of molecular endocrinology, behavioral medicine, and healthcare accessibility. Innovations no longer focus only on preventing ovulation; instead, they aim to reduce real-world contraceptive failure, improve safety perception, and empower patient-directed care.

NEXTSTELLIS AND THE INTRODUCTION OF ESTETROL-BASED OCPS

In April 2021, the USFDA approved Nextstellis, the first OCP to utilize estetrol (E4), a plant-derived estrogen that closely mimics the natural hormone found in the human body. Estetrol is a naturally occurring fetal estrogen synthesized in the human liver during pregnancy. Unlike synthetic estrogens, estetrol demonstrates selective estrogen receptor modulation, exerting central suppression of ovulation while producing comparatively weaker hepatic stimulation. Estetrol provides a more favorable metabolic profile and reduced thrombotic risk, making it a safer option for women concerned about cardiovascular complications. As a bioidentical hormone, estetrol provides a more natural and tolerable alternative for individuals seeking estrogen formulations and hormone analogs with fewer systemic impacts.[15,16] This development represents a conceptual change in contraceptive pharmacology. Earlier generations attempted to improve safety by decreasing estrogen dose. Estetrol instead modifies estrogen behavior, suggesting a future direction in which hormonal quality, rather than quantity, becomes the principal determinant of safety.

OTC ACCESSIBILITY: EXPANDING REACH

A pivotal advancement in contraceptive access occurred with the FDA's approval of Opill (norgestrel) for OTC use in 2021. This development removed the need for a physician's prescription, thus eliminating barriers that disproportionately affected underserved or rural populations.[7] Following its nationwide pharmacy rollout in 2023, Opill has expanded reproductive autonomy by enabling broader access to contraception and reproductive health decisions. Additionally, with ongoing real-world studies currently evaluating adherence rates, it provides critical insights into its impact and effectiveness outside controlled clinical trials.[16]

From a public-health perspective, this transition is comparable to making emergency contraception widely accessible. The progestin-only pill is particularly suitable for non-prescription status because it lacks estrogen-related thrombotic risk and has fewer medical contraindications. As a result, contraception is shifting from a physician-controlled therapy toward a self-care preventive medication similar to vaccines or OTC analgesics.

DIGITAL HEALTH INTEGRATION AND AI-ENABLED MONITORING

Pharmacological efficacy of OCPs exceeds 99% with correct use, yet real-world effectiveness is lower due to missed doses. Therefore, the central problem in OCPs is behavioral rather than biochemical. Between 2021 and 2024, digital health tools have transformed the contraceptive landscape. FDA-cleared mobile apps such as Spot On® and Planned Parenthood Direct now integrate with smart blister packs that track pill intake and issue real-time adherence reminders, reducing the likelihood of missed doses.[8,17]

Recent integration with wearable devices like Fitbit® has enabled continuous monitoring of contraceptive side effects such as mood changes and breakthrough bleeding (39). Clinical trials report a 30% reduction in missed doses when these AI-enhanced tools are used, underscoring their potential to personalize contraceptive care.[16]

Head-to-head comparisons between standard 28-day blister packs and the Clyk™ dispenser-featuring both visual and optional acoustic alarms that record every pill removal-demonstrated significantly fewer missed doses among the users of the digital dispenser.[8] Redesigned blister packs for elderly populations were preferred by 85% of participants, reducing pill dropping and improving usability. Smart (electronic) blister packaging has demonstrated high monitoring accuracy and strong user acceptance, though suggestions for design improvements persist.[8,9]

In accordance with the digital health tools, it is found that there is a significant advancement in personalized

contraceptive care. A 2023 randomized controlled trial published in BMC Digital Health evaluated Tuune®, a web-based personalized contraceptive decision aid that matches users with the most appropriate OCP based on hormonal profiles and personal health preferences. The study findings indicate significant improvements in reproductive health knowledge, decision-making confidence, and self-efficacy among users.[11,13] Collectively, these digital innovations reflect a broader shift toward individualized contraceptive care. Integration of technology is empowering both clinicians and patients to tailor contraceptive strategies to medical, lifestyle, and psychological factors, ultimately enhancing adherence and outcomes.[11,13]

ECO-FRIENDLY FORMULATIONS AND SUSTAINABLE PACKAGING

The contraceptive industry is undergoing a notable transformation towards sustainability. The use of plant-based hormones such as estetrol in Nextstellis contributes to more eco-friendly production process.[19] In 2023, several major brands introduced biodegradable blister packs, aligning with the United Nations Sustainable Development goals.[11] By 2025, an estimated 60% of manufacturers are expected to commit to carbon-neutral production, reflecting a major shift toward environmental responsibility in the pharmaceutical manufacturing.[18,19]

PERSONALIZED PROGESTINS AND PHARMACOGENETIC INNOVATIONS

From 2022 to 2025, the development of condition-specific progestin formulations has enabled a more targeted therapeutic approach. For instance, desogestrel and norgestimate are now increasingly favored for managing hyperandrogenic symptoms such as acne and hirsutism. At the same time, drospirenone-based OCPs (e.g., Yaz, Yasmin) are recommended for women with PCOS and elevated cardiovascular risk profiles. Moreover, the advent of pharmacogenetic testing-expected to gain traction in clinical use by 2024-aims to personalize progestin selection based on CYP enzyme metabolism, thereby optimizing safety and enhancing efficacy for users.[19]

NON-ORAL HORMONAL DELIVERY: TOWARD GREATER FLEXIBILITY

Innovative non-oral delivery systems are redefining how contraception is administered. A new generation of vaginal rings, also known as Ring 2.0, is currently under FDA review. The Ring 2.0 is designed to deliver continuous hormone release for 6 months with customizable dosing levels. In parallel, microarray patches, in advanced clinical trials, provide a painless, 7-day transdermal delivery option with high efficacy and minimal user intervention.[4] These approaches aim to reduce pill fatigue, enhance compliance, and provide women with greater control over their contraceptive regimens.[20-23] Expanding delivery methods beyond oral administration: non-oral delivery systems, such as transdermal patches and vaginal rings, offer significant user convenience by providing reliable hormone delivery without the need for daily pill intake. These methods enhance adherence and broaden contraceptive choices.[4,24]

ENHANCING SAFETY PROFILES OF OCPS

Safety optimization has been the principal driver of OCPs development over the past 5 decades. Because OCPs are administered to healthy individuals for long durations, acceptable risk thresholds are significantly lower than for most therapeutic drugs. Consequently, even rare adverse effects have guided major formulation changes. Significant research has focused on improving the safety of OCPs.

The most clinically relevant adverse effect of combined OCPs is VTE. Estrogen stimulates hepatic synthesis of coagulation factors and reduces anticoagulant protein activity, creating a prothrombotic state. Contemporary low-dose formulations have markedly reduced thrombotic risk compared with early high-dose pills. The development of new progestins aims to mitigate the cardiovascular risks historically associated with earlier formulations, while compromising contraceptive efficacy.[5,25] In addition, modern formulations strive to minimize adverse metabolic effects, such as insulin resistance and disturbances in lipid profiles, thereby safeguarding the metabolic health of users.[26] Furthermore, formulation advances have improved compatibility with commonly used medications, lowering the risk of interactions and ensuring the effectiveness of both OCPs and concomitant therapies.[3,4] Drug interactions remain an important practical safety issue. Hepatic enzyme inducers such as rifampicin, carbamazepine and phenytoin accelerate steroid metabolism and may reduce contraceptive efficacy. Conversely, most commonly used antibiotics do not significantly alter hormone levels, a misconception that historically contributed to unnecessary discontinuation. This is particularly beneficial for women managing other medical conditions.[27] Overall, safety improvements in modern OCPs have resulted primarily from dose reduction, improved receptor selectivity and better patient screening rather than from a pharmacological breakthrough.

IMPROVING USER EXPERIENCE AND ACCESSIBILITY

The goal of new developments is to help women use OTC OCPs more easily and safely, as seen in the Figure 2. Smart blister packs integrated with mobile applications provide timely reminders for pill intake, significantly enhancing user compliance and reducing missed doses.[8,28]

Some newer OCP formulations offer more stable and consistent hormone release, minimizing hormonal fluctuations and associated side effects, leading to a more comfortable user experience.[8,29] The exploration of OTC

availability for certain OCPs promises greater accessibility, removing the prescription barrier and empowering women with more autonomous and convenient contraceptive decision-making.[30]



Figure 2: Hormonal dose optimization in oral contraceptives: 1980 vs. 2020.

POTENTIAL FUTURE DEVELOPMENTS

The field of contraception is rapidly advancing, with several promising developments exploring hormonal and non-hormonal options. Researchers are exploring non-hormonal options like improved intrauterine devices (IUDs), barrier methods, and natural fertility tracking techniques to offer more choices beyond hormone-based methods. At the same time, digital health tools such as smartphone apps and wearable devices are being designed to help women monitor pill usage, manage side effects, and receive alerts about possible drug interactions-making contraceptive use more personalized and empowering. There is also a growing focus on sustainability among companies, thus shifting toward eco-friendly packaging and environmentally responsible production practices. Additionally, new hormonal pills like Nextstellis, which uses a plant-based estrogen called estetrol, represent a major step forward in offering safer and more natural contraceptive options.[31]

In recent years, OCPs have seen significant improvements while focusing on enhancing safety, efficacy, and reliability for users. A key development of low-dose pills**,** which contain smaller amounts of estrogen and progestin content, reduces common side effects like weight gain, mood changes, and breast tenderness, while still working well to prevent pregnancy.[4] These advanced low-dose options are beneficial, especially for women who can't tolerate earlier high-dose pills. Additionally, phasic OCPs have been introduced, which adjust hormone levels at different points in the cycle to better match the body's natural rhythm and reduce side effects even further.[32]

The adoption of extended-cycle and continuous regimens has also gained popularity for reducing the frequency of menstruation. By decreasing the number of menstrual periods per year, these regimens offer greater convenience, improved compliance, and enhanced quality of life, especially for women who suffer from dysmenorrhea, anemia, or menstrual migraines.[4] This shift empowers women with greater flexibility and control over their menstrual cycles.[33] Advancements have also led to the development of personalized and customizable OCPs, allowing for hormonal therapy to be tailored to individual physiological profiles and health needs. These options are especially valuable for women with specific medical conditions such as PCOS and endometriosis, as they aim to reduce side effects while optimizing therapeutic outcomes.[3] This personalization marks a transition toward more patient-centric contraceptive solutions.[34]

Furthermore, condition-specific formulations expand therapeutic possibilities, i.e., OCPs designed to meet the unique needs of different women. For example, Yasmin and Yaz**,** the most frequently recommended pills, which contain drospirenone, are often recommended for women with acne-prone skin. However, the patient's higher risk of heart problems requires caution. Camrese is designed for extended-cycle use and is especially helpful for women who experience heavy menstrual bleeding, as it reduces the number of periods each year. Pills containing desogestrel and norgestimate are commonly used to manage high levels of male hormones (hyperandrogenemia), which can cause symptoms like acne and excessive hair growth**.** Tibolone**,** although not mainly used for contraception, is a hormone therapy option for postmenopausal women and helps with symptoms like bone loss and hot flashes.[35]

Mutually, these developments represent a paradigm shift in contraceptive care, moving from standardized formulations toward more individualized, accessible, and condition-specific therapies that prioritize women's health, lifestyle preferences, and therapeutic goals.[36] The continuous commitment of researchers, healthcare professionals, and pharmaceutical companies to improving the safety, efficacy, accessibility, and user experience of OCPs underscores the critical role of this contraceptive method. Recent advancements in formulations, safety profiles, and user-centric innovations, coupled with promising future developments across hormonal and non-hormonal spheres, pave the way for better, safer, and more accessible birth control options. These collective efforts empower individuals to confidently manage their reproductive health.[37] Recent improvements in contraceptive pills focus on making them work well, cause fewer side effects, and provide a more comfortable experience for women. Low-dose OCPs deliver reduced hormone levels to mitigate common adverse effects like weight gain, mood swings, and breast tenderness. There is also a significant move towards personalization, with customizable OCPs and hormonal regimens being developed to tailor treatment to individual hormonal

profiles and specific medical needs, such as managing PCOS, endometriosis, or hormone replacement therapy (HRT).

Furthermore, non-oral delivery methods, including transdermal patches and vaginal rings, offer consistent hormone delivery, bypassing the gastrointestinal tract and eliminating the need for daily pill intake, thereby improving convenience and adherence.[38] Phasic OCPs are designed to mimic the body's natural menstrual hormone cycle more closely. They contain varying levels of estrogen and progestin in different phases of the 21-day cycle. This change in hormone levels helps reduce side effects such as mood swings, breakthrough bleeding, and nausea that may occur with monophasic pills (which have the same hormone dose every day). Phasic pills are especially useful for women who experience hormonal fluctuations or side effects with standard formulations.[27]

Future contraceptive research is increasingly focused on acceptability rather than only potency. Earlier generations of contraceptive research emphasized hormonal suppression of ovulation, whereas current priorities include minimizing adverse effects, improving cycle control, and enhancing patient satisfaction. As reproductive healthcare moves toward patient-centered models, the success of a contraceptive method will likely be measured by continuation rates and quality-of-life outcomes rather than solely biological efficacy

PERSONALIZED AND CUSTOMIZABLE OCPS

Targeted formulations

For women experiencing heavy menstrual bleeding, Camrese, an extended-cycle OCP, offers a practical solution by reducing the frequency of periods and the volume of blood loss. Aranelle is considered suitable for obese women and those with PCOD, providing balanced hormonal control with improved metabolic tolerability. Tibolone, though not primarily a contraceptive, is widely used in HRT for postmenopausal women, offering benefits in managing symptoms like osteoporosis and vasomotor disturbances. Finally, OCPs containing desogestrel or norgestimate are particularly beneficial for women with hyperandrogenemia, as these progestins help reduce androgen levels, addressing symptoms such as hirsutism and acne.[25]

Safety improvements

Infographic Figures 3 and 4 illustrate the comparison of high-dose and low-dose OCPs and their side effects on the menstrual frequency difference between a traditional 28-day oral contraceptive regimen and an extended-cycle regimen. The extended-cycle option leads to approximately 74% fewer periods, improving convenience (clock icon) and quality of life (smiley icon), while maintaining contraceptive effectiveness.

Table 1: Personalized Uses of OCPs.

Conditions	Brand name(s)	Key hormonal component	Purpose
Acne-prone skin	Yasmin/Yaz	Drospirenone	Reduces acne through anti-androgenic effects
Heavy menstrual bleeding	Camrese	Levonorgestrel + ethinyl estradiol	Reduces menstrual frequency and blood volume (4 periods/year)
Hyperandrogenism	Desogestrel/ Norgestimate	Desogestrel/ Norgestimate	Manages high androgen symptoms (acne, hirsutism)
Postmenopausal symptoms	Livial®, Tibofem®, Boltin®	Tibolone	Relieves hot flashes/night sweats, vaginal atrophy, and prevents osteoporosis



Figure 3: Comparison of high-dose vs. low-dose OCPs and their side effect profiles.



Figure 4: Comparison of standard vs. extended-cycle oral contraceptive regimens.



Figure 5: Comparison of how standard and extended-cycle contraceptives affect menstrual frequency.

Above Figure 5: shows graphical comparison of standard and extended cycle effect on menstrual frequency. The evolution of OCPs has been marked by substantial improvements in safety, particularly in reducing both cardiovascular and metabolic risks, Modern formulations now include newer-generation progestins that demonstrate a reduced risk of thromboembolism and cardiovascular complications compared to older synthetic versions.[5] These advancements ensure that contraceptive efficacy is maintained while minimizing adverse impacts on the vascular system.[25] Efforts have also been made to mitigate metabolic side effects commonly associated with hormonal contraception with contemporary OCPs designed to reduce the incidence of insulin resistance and lipid profile disturbances, thus supporting better long-term metabolic health in users.[6] These developments helped women with pre-existing metabolic conditions such as PCOS or obesity.[39]

Additionally, refinements in drug interaction profiles allow for improved compatibility with a wide range of commonly prescribed medications, increasing the safety and efficacy of OCPs for women managing multiple health concerns or undergoing polypharmacy.[3] Collectively, these improvements contribute to a more favorable safety profile, enhancing the acceptability and usability of OCPs for diverse patient populations.[39]

CLINICAL AND PUBLIC-HEALTH PERSPECTIVE

The evolution of OCPs illustrates a broader transition in medicine from disease treatment toward preventive pharmacotherapy. Unlike most medications, OCPs are prescribed to healthy individuals for long durations; therefore, their acceptability depends not only on biological safety but also on perceived risk, accessibility, and user autonomy. The major limitation of oral contraception in real-world settings is not pharmacologic failure but inconsistent use. Perfect-use failure rates are extremely low, whereas typical-use failure remains significantly higher, emphasizing that adherence behaviour rather than hormonal efficacy determines population-level effectiveness.[27,37]

From a clinical standpoint, modern prescribing has shifted from a "one-pill-fits-all" approach to individualized selections.[4,25] Combined oral contraceptives are now chosen according to comorbidities, patient priorities, and risk profile. For example, anti-androgenic formulations are preferred in acne and hyperandrogenism, extended regimens in endometriosis or dysmenorrhea, and progestin-only pills in women with contraindications to estrogen. This reflects recognition that OCPs act as endocrine modulators rather than solely contraceptive agents. Consequently, their therapeutic value often extends beyond pregnancy prevention.

Public-health considerations further influence contraceptive effectiveness. Barriers such as prescription requirements, travel distance, cost, and sociocultural concerns frequently limit consistent use. The introduction of OTC progestin-only pills represents an attempt to address structural barriers rather than pharmacologic limitations.[7,8,33] Increasing accessibility is likely to have a greater impact on unintended pregnancy rates than further minor changes in hormone composition.

Another emerging determinant of effectiveness is behavioural technology. Digital reminder systems, telemedicine consultations, and smart packaging target the primary cause of contraceptive failure-missed dosing. These tools effectively enhance pharmacologic efficacy by improving adherence, suggesting that future improvements in oral contraception may arise more from healthcare delivery innovation than molecular modification.[9,10,39]

Thus, modern oral contraceptive therapy should be viewed as a combination of pharmacology, behavioural medicine, and health-system design. The most effective contraceptive is not merely the one with optimal hormonal composition but the one that a patient can use consistently, safely, and confidently.

CONCLUSION

In conclusion, the evolution of OCPs has led to significant improvements in safety, effectiveness, and user convenience. Driven by innovations such as low-dose and phasic formulations, digital health tools, OTC access, and personalized options, contraception is more accessible and patient-friendly. These advances reflect the dedication of healthcare professionals and pharmaceutical researchers to supporting women's reproductive health through informed and individualized choices. The ongoing commitment of researchers, healthcare professionals, and pharmaceutical companies to enhancing the safety, efficacy, and user experience of OCPs underscores the importance of this vital contraceptive method. The continuous pursuit of innovation in OCPs reflects a dedication to addressing the evolving needs and preferences of individuals seeking effective and convenient contraception. Researchers, doctors, and pharmaceutical companies are continuously working to improve the safety, effectiveness, and convenience of OCPs. Their efforts show a strong commitment to creating better birth control options that meet the changing needs of modern women. As a result, the future of contraceptive pills looks promising-with more personalized, safer, and accessible choices for everyone.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Gandhi AB, Supe PA. Evolution of oral contraceptive pills: historical perspective and modern advances. J Obstet Gynaecol India. 2024;74:109-12.
2. Cameron NA, Blyler CA, Bello NA. Oral Contraceptive Pills and Hypertension: A Review of Current Evidence and Recommendations. Hypertension. 2023;80(5):924-35.
3. Criss B. New Hormonal Contraceptives and New Roles for Established Hormonal Contraceptives. Current Pediatrics Rep. 2023;11(4):1-62023.
4. Teal S, Edelman A. Contraception selection, effectiveness, and adverse effects: a review. JAMA. 2021;326(24):2507-18.
5. Basile JN, Bloch MJ. Hormonal contraception in women with hypertension and other cardiovascular risk factors. UpToDate. Waltham, MA. 2025.
6. Sivasankaran S, Jonnalagadda S. Advances in controlled release hormonal technologies for contraception: a review of existing devices, underlying mechanisms, and future directions. J Control Release. 2020;330:797-811.

7. Gizaw Z, Astale T, Kassie GM. What improves access to primary healthcare services in rural communities? A systematic review. BMC Primary Care. 2022;23(1):313.
8. Katherine K, Alexandra W, Charon A, Maricela C, Alyssa L, Raquel ZR, et al. Challenges accessing contraceptive care and interest in over-the-counter oral contraceptive pill use among Black, Indigenous, and people of color: an online cross-sectional survey. Contraception. 2023;120:109950.
9. Kiyomi S, Mikio M, Masaho H, Hiroyuki U, Kiyoshi K. Evaluation of newly designed blister packs for easier handling to prevent pill dropping. Patient Prefer Adherence. 2022;16:2543-58.
10. Izzah Z, Zijp TR, Åberg C. Electronic smart blister packages to monitor and support medication adherence: a usability study. Patient Prefer Adherence. 2022;16:2543-58.
11. Lina El T, Dalia K, Antoine AAM, Ali K, Sehrish A, Joseph N. Efficacy of dienogest vs combined oral contraceptive for pain associated with endometriosis: a randomized study. Europ J Obstet Gynecol Reproduct Biol. 2021;267:205-12.
12. Howard SA, Benhabbour SR. Non-Hormonal Contraception. J Clin Med. 2023;12(14):4791.
13. Summer M, Matthew E, Stephen AB, Laura JP, Emma R, Chris R, et al Tuuned in: use of an online contraceptive decision aid for women increases reproductive self-efficacy and knowledge; results of an experimental clinical trial. BMC Digital Health. 2023;1(1):1-11.
14. Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2017-2019. NCHS Data Brief, no 388. Hyattsville, MD: National Center for Health Statistics. 2020.
15. ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI; Panay N, Anderson RA, Bennie A, Cedars M, Davies M, Ee C, et al. Evidence-based guideline: premature ovarian insufficiency. Climacteric. 2024;27(6):510-20.
16. Bhatt A. Applied intelligence in clinical drug development: Potential benefits and emerging concerns. Perspect Clin Res. 2025;16(3):127-31.
17. Kimberly D, Joyce CA. Current Contraceptive Status Among Women Aged 15-49: United States, 2017-2019. NCHS Data Brief No. 388, 2020. Available at: https://www.cdc.gov/nchs/products/databriefs/db388.htm. Accessed on 02 February 2026.
18. Gilbert AL, Hoffman BL. Contraceptive Technology: Present and Future. Obstet Gynecol Clin N Am. 2021;48(4):723-35.
19. Douxfils J, Klipping C, Duijkers I, Virginie K, Marie M, Catherine M, et al. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception. 2020;102(6):396-402.
20. Gemzell-Danielsson K, Cagnacci A, Chabbert-Buffet N, Jonathan D, Jean-Michel F, Ali K, et al. A novel estetrol-containing combined oral contraceptive: European expert panel review. Europ J Contracept Reproduct Health Care. 2022;27(5):373-83.
21. Emerson C. Habiller des statues. Studia Bruxellae. 2024;15(1):102-9.
22. Datta ST, Kumar U. Mind the Gaps: Cases in Gynaecology, Sexual and Reproductive Health E-Book. Elsevier Health Sciences. 2021.
23. Cohen M, Posner S, Kent C, Antoinette T. Nguyen; Kathryn M. Curtis; Naomi K. Tepper. Morbidity and Mortality Weekly Report Centers for Disease Control and Prevention MMWR Editorial and Production Staff (Serials) MMWR Editorial Board CONTENTS. 2024. Available at: https://www.cdc.gov/mmwr/volumes/73/rr/pdfs/rr7304a1-H.pdf. Accessed on 02 February 2026.
24. Zheng A, Nelson HN, McCall-Hosenfeld JS, Erik B, Lehman MS, Cynthia H. Chuang: Recent Intimate Partner Violence and Oral Contraceptive Pill Adherence in a Cohort of Reproductive-Aged Women. J Women's Health. 2022;31(12):1703-9.
25. Hillen C, Sachs C, Buhling KJ, Monserat E, Sebastian G, Juliana V, et al. Evaluating Patient-Reported Adherence And Safety for Oral Contraception Treatment in Women via a Direct-To-Consumer Prescription Platform: A Cross-Sectional Study. Telemed J e-Health. 2024;30(12):2876-82.
26. Bennink C, Gennip M, Gerrits MGF, Egberts JFM, Gemzell-D. Health benefits of combined oral contraceptives-a narrative review. Europ J Contracept Reproduct Health Care. 2024;29(2):40-52.
27. Harris ML, Egan N, Forder PM, Deborah B, Aaron LS, Vanessa EM, et al. Patterns of contraceptive use among young Australian women with chronic disease: findings from a prospective cohort study. Reproductive Health. 2022;19(1):111.
28. Bearak J, Maddow-Zimet I, Leong E, Kost K. O16Contraceptive failure rates: New estimates for individual methods and method combinations. Contraception. 2022;116:73.
29. Seidu AA, Ameyaw EK, Ahinkorah BO, Leonard B, Samuel D, Augustine A, et al. Sexual and reproductive health education and its association with ever use of contraception: a cross-sectional study among women in urban slums, Accra. Reproductive Health. 2022;19(1):7.
30. Dehlendorf C, Fox E, Silverstein IA, Alexis H, Reiley R, Kelsey H, et al. Development of the Patient-Centered Contraceptive Counseling scale (PCCC), a short form of the Interpersonal Quality of Family Planning Care scale. Contraception. 2021;103(5):310-5.
31. Xie H, Li Y, Wen C, Wang Q. Contraceptive Use Disparities in Asian American Women in 2015-2016: California Health and Interview Survey. Sexes. 2024;5(3):386-97.
32. Otte R, Thissen VTM, Mulder BC. (Dis)continuation of the oral contraceptive pill: A focus group approach in the Netherlands. Heliyon. 2023:e19405.
33. Rothschild CW, Richardson BA, Guthrie BL, P Kithao, T Omurwa,J Mukabi, et al. Contributions of

side effects to contraceptive discontinuation and method switch among Kenyan women: a prospective cohort study. 2022;129(6):926-37.
34. Fuentes L, Douglas-Hall A, Geddes CE, Megan L. Kavanaugh: Primary and reproductive healthcare access and use among reproductive aged women and female family planning patients in 3 states. ProQuest. 2023:e0285825.
35. Gozzi P, Persson M, Nielsen A, Kilander H, Kågesten AE, Iwarsson KE, et al. Contraceptive access and use among women with migratory experience living in high-income countries: a scoping review. BMC Public Health. 2024;24(1):2569.
36. Shumet T, Geda NR, Hassan JA. Barriers to modern contraceptive utilization in Ethiopia. Contracept Reproduct Med. 2024;9(1):47.
37. Congy J, Bouyer JE. Low-income women and use of prescribed contraceptives in the context of full health insurance coverage in France, 2019. Contraception. 2023;121:109976.
38. Liddelow C, Mullan B, Boyes M. Adherence to the oral contraceptive pill: the roles of health literacy and knowledge. Health Psychol Behavioral Med. 2020;8(1):587-600.
39. Wondimagegene YA, Debelew GT, Koricha ZB. Effectiveness of peer-led education interventions on contraceptive use, unmet need, and demand among adolescent girls in Gedeo Zone, South Ethiopia. A cluster randomized controlled trial. Global Health Action. 2023;16(1):2160543.

Cite this article as: Rajopadhye B, Dhakne A. Recent advances in oral contraceptive pills: a review of evolving formulations and innovations. Int J Reprod Contracept Obstet Gynecol 2026;15:1476-86.